{
    "root": "de53523f-624f-492d-8d2f-027bbd7ce5f3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eribulin Mesylate",
    "value": "20250307",
    "ingredients": [
        {
            "name": "ERIBULIN MESYLATE",
            "code": "AV9U0660CW"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "NITROGEN",
            "code": "N762921K75"
        }
    ],
    "indications": "eribulin mesylate injection microtubule inhibitor indicated treatment patients : metastatic breast cancer previously received least two chemotherapeutic regimens treatment metastatic disease . prior therapy included anthracycline taxane either adjuvant metastatic setting . ( 1.1 ) unresectable metastatic liposarcoma received prior anthracycline-containing regimen . ( 1.2 )",
    "contraindications": "administer 1.4 mg/m 2 intravenously 2 5 minutes days 1 8 21-day cycle . ( 2.1 ) reduce dose patients hepatic impairment moderate severe renal impairment . ( 2.1 ) mix drugs administer dextrose-containing solutions . ( 2.3 )",
    "warningsAndPrecautions": "ndc 71731-4171-1 injection : 1 mg/2 ml , single-dose vial . one vial per carton . store 20º 25ºc ( 68º 77ºf ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . freeze refrigerate . store vials original cartons . eribulin mesylate injection colourless clear liquid . eribulin mesylate injection cytotoxic . follow applicable special handling disposal procedures.¹",
    "adverseReactions": "none .",
    "indications_original": "Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 )",
    "contraindications_original": "Administer 1.4 mg/m 2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. ( 2.1 ) Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. ( 2.1 ) Do not mix with other drugs or administer with dextrose-containing solutions. ( 2.3 )",
    "warningsAndPrecautions_original": "NDC 71731-4171-1      \n                  Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton.\n                  Store at 20º to 25ºC (68º to 77ºF); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Do not freeze or refrigerate. Store the vials in their original cartons.\n                  Eribulin mesylate injection is colourless and clear liquid.\n                  Eribulin mesylate injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹",
    "adverseReactions_original": "None."
}